After three years at the helm of the Federal Trade Commission
(FTC), Chairman Jon Leibowitz stepped down. Without a doubt
Chairman Leibowitz has been a visible and relentless advocate for
restricting pay-for-day or reverse payment generic pharmaceutical
patent dispute settlements and for expanding the reach of Section 5
of the Federal Trade Commission Act, 15 U.S.C. §45.
FTC v. Watson, which is set for oral argument on March
25, 2013 before the U.S. Supreme Court, should decide the antitrust
standard applicable to reverse payment settlements. There, the FTC
is arguing that reverse payment agreements should be treated as
presumptively unlawful because, according to the FTC's brief in
the Supreme Court, they closely resemble the sort of horizontal
agreements that have previously been condemned under the antitrust
laws. The standard applied in most circuits is the "scope of
the patent" test—reverse payment settlements are lawful
as long as the settlement does not exceed